Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial
Neoadjuvant enzalutamide and ADT was associated with favorable long-term oncologic outcomes, supporting continued investigation in localized PCa.
Authors
- Sandeep Gurram (ORCID: https://orcid.org/0000-0002-6405-9269)
- Barış Türkbey (ORCID: https://orcid.org/0000-0003-0853-6494)
- Peter A. Pinto (ORCID: https://orcid.org/0000-0002-0190-5931)
- Lauren Loebach
- Rubén Blachman-Braun (ORCID: https://orcid.org/0000-0001-9700-0805)
- Nikhil Pramod
- Jasmeen Saini (ORCID: https://orcid.org/0000-0003-0601-8271)
- Fatima Karzai (ORCID: https://orcid.org/0000-0002-3244-1332)
- Braden Millan (ORCID: https://orcid.org/0000-0002-4253-8568)
- Milan Patel
Institutions
- National Institutes of Health (US)
- National Cancer Institute (US)
Publication Details
- Journal
- The Prostate
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1002/pros.70093
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- National Institutes of Health